AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469

口服 SCIO-469 的功效、安全性和耐受性的开放标签研究

• 批准号: 7368175
• 负责人: AMRITA KRISHNAN
• 金额: $ 0.22万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7368175
• 关键词: OPEN; LABEL; STUDY; EFFICACY; SAFETY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Multiple Myeloma (MM) is an incurable malignancy with a median survival of approximately three years with standard therapy. It accounts for 10% of malignant hematologic neoplasm with an estimated 10,800 deaths per year. The high mortality and morbidity of the disease, coupled with recent increased understanding of the role of cytokines in the pathogenesis of MM, have stimulated investigations using novel treatments that offer the potential to improve patient outcome. SCIO-469, an orally active new chemical entity that inhibits p38a mitogen-activated protein kinase (MAPK), with demonstrated anti-inflammatory and disease-modifying properties currently in Phase II clinical development for rheumatoid arthritis, has shown the ability to influence the cytokines, IL-6, vascular endothelial growth factory (VEGF), TNFa, and IL-1B involved in the pathogenesis of MM. P38a MAPK mediates the production of proinflammatory cytokines and other factors, including prostaglandin (PGE)2 receptor activator of nuclear factor-kB ligand (RANKL), and IL-11, that affect the pathogenesis of MM.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。多发性骨髓瘤（MM）是一种无法治愈的恶性肿瘤，标准治疗的中位生存期约为3年。它占恶性血液肿瘤的10%，估计每年有10,800人死亡。该疾病的高死亡率和发病率，加上最近对细胞因子在MM发病机制中的作用的了解增加，刺激了使用新治疗方法的研究，这些治疗方法有可能改善患者的预后。SCIO-469是一种口服活性的新型化学实体，可抑制p38a丝裂原活化蛋白激酶（MAPK），具有抗炎和改善疾病的特性，目前正在类风湿关节炎的II期临床开发中，已显示出影响MM发病过程中涉及的细胞因子、IL-6、血管内皮生长工厂（VEGF）、TNFa和IL-1B的能力。p38a MAPK介导促炎细胞因子和其他因子的产生。包括前列腺素（PGE）2受体激活剂核因子- kb配体（RANKL）和IL-11，它们影响MM的发病机制。